

Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience

Yair Herishanu, Neta Goldschmidt, Osnat Bairey, Rosa Ruchlemer, Riva Fineman, Naomi Rahimi-Levene, Lev Shvidel, Tamar Tadmor, Aviv Ariel, Andrea Braester, Mika Shapiro, Erel Joffe and Aaron Polliack and on behalf of the Israeli CLL Study Group

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014.115808

Manuscript received on October 5, 2014. Manuscript accepted on January 29, 2015.

Correspondence: yairh@tlvmc.gov.il

Supplementary Methods:

Late-onset neutropenia was defined as a new grade 3-4 neutropenia, occurring at least 4 weeks after the last treatment with rituximab and after recovery of the neutrophil count to near-normal or normal limits. (1)

.1 Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. *Medicine*. 2010 Sep;89(5):308-18.

Supplementary Figure:

Outcomes for age subgroups of < 65 years and between 65-70 years.

Parameter	<65 years (n=110)	65-70 years (n=18)	p-value
≤2/3 FC dose (% of patients)	11.9	22.2	0.17
Overall response rate (% of patients)	92.5	94.4	1.0
Complete response rate (% of patients)	72.9	55.5	0.14
Progression free survival (median, months)	43.0	27.2	0.19
Overall survival (median, months)	99.5	65.1	0.28